M&AAngelini inks $4.1B Catalyst takeover to fuel US expansionItaly’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market. more ➔
InflaRx InflammationInflaRx attracts strong investor interest with US share offering turning to kidneyAs Amgen’s competing therapy has come under growing regulatory scrutiny, an opportunity has emerged for InflaRx N.V. to position its own oral C5aR inhibitor in the market. The Jena-based biotech company … more ➔
Venture CapitalScarlet raises £3.2 million to advance lab-grown red blood cell therapiesScarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have … more ➔
BayerBayerFor several billions: Bayer adds Perfuse Therapeutics to portfolio of eye therapiesBayer AG is strengthening its ophthalmology portfolio with the acquisition of Perfuse Therapeutics for up to $2.45bn. The focus is on a Phase II candidate for glaucoma and diabetic retinopathy with potential … more ➔
ReportSwitzerland’s biotech sector defies tough markets with record revenueIf one follows the figures in the Swiss Biotech Report 2026, the green lights are more prominent than the red warning signals. The Swiss biotech industry continued its growth momentum in 2025 and even … more ➔
Sevan Habeshian & Christian Heinis et al. https://www.nature.com/articles/s41467-022-31428-Drug DesignMacrocycles: big is the new beautifulIn the evolving landscape of drug discovery and new design, scientists and pharmaceutical innovators continually strive to develop therapies that are both highly selective and clinically effective, … more ➔
Getty Images, for Unsplash+Asthma, COPDSwiss Windward Bio adds US$165m to its Chinese pipelineBasel-based Windward Bio did it again and has raised another three-digit millions – $165 million to be exact – to advance a pipeline of long-acting immunology therapies—much of it sourced through … more ➔
Venture CapitalCytospire raises £61M to take gamma-delta T-cell engager into the clinicCytospire Therapeutics has raised a £61 million (€71 million) Series A round, positioning the British biotech to advance pan-gamma-delta T-cell engagers (TCEs) into cancer clinical trials. more ➔
M&AUCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager pushBelgian biopharma UCB has moved quickly from testing the waters in autoimmune T-cell engagers to making one of the largest bets yet on the modality, agreeing to acquire San Diego-based Candid Therapeutics … more ➔
Planet Volumes via Unsplash+FinancingBioOrbit: record seed round for in‑space drug manufacturingCan in‑space manufacturing help cancer patients take complex medicines at home? For a technology that aims to do just that, UK‑based BioOrbit has just raised £9.8m (around €11.3m) – the “world’s … more ➔
InflaRx 
Bayer
Sevan Habeshian & Christian Heinis et al. https://www.nature.com/articles/s41467-022-31428-
Getty Images, for Unsplash+
Planet Volumes via Unsplash+